Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants

Asunción Mejías, Octavio RamiloDivision of Pediatric Infectious Diseases, The University of Texas Southwestern Medical Center and Children’s Medical Center, Dallas, Texas, USAAbstract: In respiratory syncytial virus (RSV) disease the balance between the in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Asunción Mejías, Octavio Ramilo
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2008
Materias:
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/831d1b34705d4b61bd5e6e3576071836
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:831d1b34705d4b61bd5e6e3576071836
record_format dspace
spelling oai:doaj.org-article:831d1b34705d4b61bd5e6e35760718362021-12-02T08:20:46ZReview of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants1177-54751177-5491https://doaj.org/article/831d1b34705d4b61bd5e6e35760718362008-09-01T00:00:00Zhttp://www.dovepress.com/review-of-palivizumab-in-the-prophylaxis-of-respiratory-syncytial-viru-a2293https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Asunción Mejías, Octavio RamiloDivision of Pediatric Infectious Diseases, The University of Texas Southwestern Medical Center and Children’s Medical Center, Dallas, Texas, USAAbstract: In respiratory syncytial virus (RSV) disease the balance between the innate and adaptive immune responses determines the expression of the pathological phenotype favoring the development of acute bronchiolitis, and in certain children the development of recurrent wheezing. While humoral antibody plays a major role in protection against disease, T-cell immunity targeted to viral proteins appears to terminate viral infection. At the moment, treatment modalities for acute RSV infection do not effectively modify the course of the disease, and RSV vaccine development has shown conflicting results. To date, however, passive immunoprophylaxis with monoclonal antibodies is the only strategy that has demonstrated consistent efficacy in reducing RSV hospitalizations in high-risk children. The potential benefit of new strategies for prevention and treatment of RSV infections should be evaluated with respect to both the acute infection as well as the chronic respiratory manifestations induced by RSV.Keywords: respiratory syncytial virus, palivizumab, infants Asunción MejíasOctavio RamiloDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 3, Pp 433-439 (2008)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Asunción Mejías
Octavio Ramilo
Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
description Asunción Mejías, Octavio RamiloDivision of Pediatric Infectious Diseases, The University of Texas Southwestern Medical Center and Children’s Medical Center, Dallas, Texas, USAAbstract: In respiratory syncytial virus (RSV) disease the balance between the innate and adaptive immune responses determines the expression of the pathological phenotype favoring the development of acute bronchiolitis, and in certain children the development of recurrent wheezing. While humoral antibody plays a major role in protection against disease, T-cell immunity targeted to viral proteins appears to terminate viral infection. At the moment, treatment modalities for acute RSV infection do not effectively modify the course of the disease, and RSV vaccine development has shown conflicting results. To date, however, passive immunoprophylaxis with monoclonal antibodies is the only strategy that has demonstrated consistent efficacy in reducing RSV hospitalizations in high-risk children. The potential benefit of new strategies for prevention and treatment of RSV infections should be evaluated with respect to both the acute infection as well as the chronic respiratory manifestations induced by RSV.Keywords: respiratory syncytial virus, palivizumab, infants
format article
author Asunción Mejías
Octavio Ramilo
author_facet Asunción Mejías
Octavio Ramilo
author_sort Asunción Mejías
title Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
title_short Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
title_full Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
title_fullStr Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
title_full_unstemmed Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
title_sort review of palivizumab in the prophylaxis of respiratory syncytial virus (rsv) in high-risk infants
publisher Dove Medical Press
publishDate 2008
url https://doaj.org/article/831d1b34705d4b61bd5e6e3576071836
work_keys_str_mv AT asunciampoacutenmejampiacuteas reviewofpalivizumabintheprophylaxisofrespiratorysyncytialvirusrsvinhighriskinfants
AT octavioramilo reviewofpalivizumabintheprophylaxisofrespiratorysyncytialvirusrsvinhighriskinfants
_version_ 1718398553288605696

Ejemplares similares